CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a

CG Oncology, Inc. (CGON) EV/FCF

Alert me on EV/FCF

As of 6 November 2026, CG Oncology, Inc. (CGON) trades at a EV/FCF of −30.6×. Over the past ten years it has ranged from −34.5× (March 2026) to 0.5× (March 2024); the current reading is higher than 7% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 −18.7× —
FY2024 −13.5× —
FY2023 0.2× 0.00%
FY2022 0.2× —

Quarterly newest first

Period EV/FCF Change
Sep 2026 −28.2× —
Jun 2026 −29.3× —
Mar 2026 −29.0× —
Dec 2025 −18.7× —
9 more quarters

Against its own ten years

Low −34.5× High 0.5×
Ten-year median −22.2×
Current reading's percentile 7

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on CGON